Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Case Study in Regulatory Innovation: Pharmacogenomics at FDA

This article was originally published in RPM Report

Executive Summary

FDA’s idea to encourage “voluntary” submission of pharmacogenomic data started slow—but the program has paid significant dividends for the agency. In addition to building knowledge and advancing the use of PKG in drug regulation, it has also won over industry and become a case study to support broader funding of regulatory science.
Advertisement

Related Content

From “Safe Harbor” To Spotlight: Pharmacogenomics Comes Of Age At FDA
The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
Commissioner Hamburg on R&D Productivity
FDA Rethinking Weight Loss Standards: A Test Case for Patient-Focused Drug Development
"Wise Policy" Needed To Link Comparative Effectiveness with Individualized Medicine
Biomarker Diagnostics: Place Your Bets Wisely
Getting Personal: FDA's Plan to Save the Drug Industry
Pharmacogenomic Data and Labeling: A Less-Safe Harbor for Existing Drugs?

Topics

Advertisement
UsernamePublicRestriction

Register

PS080844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel